MBX Biosciences, Inc. Common Stock
MBX - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.69B
Close$
$2.05
96.1% downside
Current Fair Value
96.1% downsideOvervalued by 96.1% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $2.69 Billion |
|---|---|
| Enterprise Value | $2.64 Billion |
| Earnings per Share | $-2.38 |
| Beta | 0.1 |
| Outstanding Shares | 47,696,363 |
Return
| Return on Equity | -25.47% |
|---|---|
| Return on Assets | -23.93% |
| Return on Invested Capital | -29.16% |
Valuation & Multiples
| P/E Ratio | -23.28 |
|---|---|
| PEG | -25.55 |
| Price to Sales | - |
| Price to Book Ratio | 6.56 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -21.96 |
| Enterprise Value to Net Income | -26 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 6, 2026
EPS Estimate
$-0.63
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.83
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0000▼ 66.25% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 2.89%▼ 113.92% |
|---|---|
| Total Invested | $80.70M▼ 97.38% |
| Investors Holding | 33▼ 149.00% |
About MBX Biosciences, Inc. Common Stock
43 employees
CEO: Mr. Peter Kent Hawryluk MBA
MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a ...